Notice of annual shareholders’ meeting in Saniona AB


PRESS RELEASE

April 24, 2018

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to attend the annual shareholders’ meeting (Sw. årsstämma) to be held at the premises of Setterwalls Advokatbyrå AB at Stortorget 23 in Malmö, Sweden on Thursday 24 May 2018 at 4.00 p.m.

Right to participate in the meeting and notice of participation
Shareholders wishing to attend the shareholders’ meeting must:

  • be registered in the company’s share register kept by Euroclear Sweden AB (the Swedish Securities Register Center) as of Friday 18 May 2018; and
  • no later than on Friday 18 May 2018 notify the company in writing of their intention to participate in the annual shareholders’ meeting to Saniona AB, Baltorpvej 154, DK-2750 Ballerup, Denmark. Such notice can also be given by email to tf@saniona.com. The notice shall specify the shareholder’s complete name, personal or company registration number, registered shareholding, address, telephone number during work hours and, when applicable, information on the number of advisors (two at the most).

Trustee-registered shares
Shareholders who have their holdings trustee-registered must temporarily register the shares in their own name in order to be entitled to participate in the annual shareholders’ meeting. Such temporary re-registration of ownership must be implemented no later than as of Friday 18 May 2018, meaning that the shareholders must well in advance before this date request their trustees thereof.

Proxies etc.
A proxy representing a shareholder must bring a written, dated and by the shareholder signed power of attorney to the annual shareholders’ meeting. The validity term of the power of attorney may be at the longest five years if this is specifically stated. In case no validity term is stated, the power of attorney is only valid for one year. Should the power of attorney be issued by a legal entity, a certified copy of a registration certificate (Sw. registreringsbevis) or equivalent document shall be presented at the meeting. In order to facilitate the preparations before the meeting, a copy of the power of attorney and other proof of authority should be attached to the notice of participation. A template power of attorney can be found at the company website (www.saniona.com) and will be sent to the shareholders who request it and state their address.

Proposed agenda

    0. Opening of the meeting.

  1. Election of chairman of the meeting.
  2. Preparation and approval of the voting list.
  3. Approval of the agenda.
  4. Election of one or two persons to verify the minutes.
  5. Consideration as to whether the meeting has been duly convened.
  6. Presentation of the annual report and the auditor’s report and the group annual report and the group auditor’s report.
  7. Resolution on
    1. adoption of the profit and loss statement and balance sheet and the group profit and loss statement and the group balance sheet,
    2. allocation of the company’s loss in accordance with the adopted balance sheet, and
    3. discharge of liability of the directors of the board and the CEO.
    4. Determination of the number of members of the board, deputy members of the board as well as the number of auditors and deputy auditors.
    5. Determination of remuneration for the board members and the auditors.
    6. Election of members of the board and accounting firm or auditors.
    7. Resolution on instruction and charter for the Nomination Committee.
    8. Determination of Remuneration Policy for senior executives.
    9. Resolution on amendment of the Articles of Association.
    10. Resolution on authorization for the board of directors regarding new issues.
    11. Resolution on (A) employee option program; and (B) directed issue of warrants and approval of transfer of warrants.
    12. Resolution on (A) option program for certain members of the board of directors; and (B) directed issue of warrants and approval of transfer of warrants.
    13. Closing of the meeting.
    14. Resolution proposals

      Item 1: Election of chairman of the meeting

      The Nomination Committee, consisting of Søren Skjærbæk, representing Jørgen Drejer, John Haurum, representing Thomas Feldthus, and Claus Braestrup who was the chairman of the board until 19 January 2018, proposes that attorney Ola Grahn is elected as chairman of the meeting.

      Item 7 (b): Resolution on allocation of the company’s loss in accordance with the adopted balance sheet

      The board of directors proposes that no dividends are paid and that available funds are carried forward to a new account.

      Item 8: Determination of the number of members of the board, deputy members of the board as well as the number of auditors and deputy auditors

      The Nomination Committee proposes that the board of directors shall be composed of five ordinary board members without deputies until the end of the next annual shareholders’ meeting. Furthermore, it is proposed that one registered accounting firm is appointed as auditor until the end of the next annual shareholders’ meeting.

      Item 9: Determination of remuneration for the board members and the auditors

      The Nomination Committee proposes that board remuneration shall be paid with SEK 275,000 to the chairman of the board (unchanged as compared with the remuneration to the chairman of the board which was resolved upon by the extraordinary shareholders’ meeting on 19 January 2018) and with SEK 110,000 to each of the members of the board who are not co-founders of Saniona AB (unchanged since previous year). Based on the proposal to the board of directors in accordance with item 10 below, remuneration is only proposed to be paid to J. Donald deBethizy, Anna Ljung and Carl Johan Sundberg. In addition, remuneration is proposed to be paid for committee work with SEK 30,000 to the chairman of the Audit Committee (unchanged as compared with the remuneration which was resolved upon by the extraordinary shareholders’ meeting on 19 January 2018). No additional remuneration is proposed to be paid for other committee work.

      Remuneration to the auditor is proposed to be paid in accordance with customary charging standards and approved invoice.

      Item 10: Election of members of the board and accounting firm or auditors

      The Nomination Committee proposes re-election of J. Donald deBethizy, Claus Braestrup, Jørgen Drejer, Anna Ljung and Carl Johan Sundberg as ordinary board members and that J. Donald deBethizy is re-elected as chairman of the board.

      The current board member Leif Andersson has declined re-election.

      The Nomination Committee proposes, in accordance with the recommendation from the Audit Committee, that Deloitte AB is re-elected as accounting firm. Deloitte AB has notified that the certified accountant Elna Lembrér Åström will continue to be the auditor in charge.

      Item 11: Resolution on instruction and charter for the Nomination Committee

      The Nomination Committee proposes that a Nomination Committee shall be appointed before coming elections and remuneration, and that an instruction and charter for the Nomination Committee shall be adopted in accordance with the following substantial terms.

      The Nomination Committee shall be comprised of three members representing the two largest shareholders as of last September, together with the chairman of the board of directors. With “largest shareholders” are meant the shareholders registered with Euroclear Sweden AB as of last September. If any of these two largest shareholders refrain from appointing an owner representative, or if an owner representative resigns or relinquishes the position before the assignment is completed and the entitled shareholder does not appoint another representative, the chairman of the board of directors shall invite the next shareholder (i.e. first the third largest owner) to within a week of the request appoint an owner representative. The procedure shall continue until the Nomination Committee is composed of three members. 

      If a substantial change of ownership occurs no later than seven weeks before the annual share-holders’ meeting, a new shareholder representative shall be appointed. The chairman of the board of directors shall then contact the one of the two largest shareholders without an owner representative and request such shareholder to appoint a representative. When such a representative has been appointed, such representative shall be a member of the Nomination Committee and replace the former member of the Nomination Committee who no longer represents one of the two largest shareholders.

      Item 12: Determination of Remuneration Policy for senior executives

      The board of directors proposes that a Remuneration Policy regarding determination of remuneration and other benefits for the managing director and other senior executives in the company shall be adopted in accordance with the following substantial terms.

      1. Fundamental principles: Remuneration shall be payable on terms that enables senior executives to be recruited and retained. Remuneration to senior executives may consist of basic salary and other customary benefits which can be considered reasonable in relation to market practice.
      2. Fixed salary: The managing director and other senior executives shall be offered a fixed salary based on the individual’s work duties, expertise, position, responsibilities, performances and other considerations. Salary shall be determined per calendar year with salary revision on 1 January each year.
      3. Variable remuneration: Saniona does not offer any variable remuneration to the managing director or other senior executives.
      4. Pensions: Saniona does not offer any separate pension benefits to the managing director or other senior executives. Certain part of the senior executive’s fixed salary is however allocated to pension payments. The proportion of such pension payments can be selected by the senior executive.
      5. Termination etc.: Upon termination by the company, the notice period for the managing director and other senior executives shall not exceed six months. However, an adjusted notice period may be applied for the managing director and the CFO during an initial period of six months after a transaction with the outcome that a majority shareholding in Saniona or Saniona A/S has been acquired by one or more persons. The adjustment shall mean that the notice period, upon termination by Saniona, may be extended to twelve months immediately after the relevant change in ownership. The notice period shall thereafter be reduced by one month for every month that passes after the change in ownership until the notice period is consistent with the normal notice period of the employment agreements. Severance payment, apart from salary during the notice period, shall not occur.
      6. Outstanding remuneration commitments: At the time of the annual shareholders’ meeting on 24 May 2018, Saniona has no outstanding remuneration commitments towards senior executives except for running commitments.
      7. Consulting assignments for board members: To the extent that a board member performs consultancy work on behalf of Saniona, in addition to the assignment as board member, consultancy fees and other remuneration for such consultancy work should be payable. Such remuneration shall be paid on market terms and the remuneration as well as other terms shall be resolved upon by the board.
      8. Deviations from the guidelines: The board of directors shall be entitled to deviate from the guidelines in individual cases if there are special reasons for doing so.


      Item 13: Resolution on amendment of the Articles of Association

      The board of directors proposes that the annual shareholders’ meeting resolves to amend the company’s Articles of Association in accordance with the following:

      § 4 Share capital and number of shares

      Current wording

      The share capital shall be not less than SEK 500,000 and not more than SEK 2,000,000. The number of shares shall be not less than 10,000,000 shares and not more than 40,000,000 shares.

      Proposed wording

      The share capital shall be not less than SEK 1,000,000 and not more than SEK 4,000,000. The number of shares shall be not less than 20,000,000 shares and not more than 80,000,000 shares.

      § 5 Board of Directors

      Current wording

      The Board of Directors shall consist of not less than three and not more than eight members with not more than two deputies.

      Proposed wording

      The Board of Directors shall consist of not less than three and not more than eight members.

      12 § Record day provision

      Current wording

      The shareholder or nominee who is registered on the record date in the share register and in a central securities depository register pursuant to Chapter 4 of the Financial Instruments Accounts Act (1998:1479) or any person who is registered in a central securities depository account pursuant to Chapter 4, Section 18 first paragraph 6-8 of the mentioned Act, shall be deemed to be authorised to exercise the rights set out in Chapter 4, Section 39 of the Companies Act (2005:551).

      Proposed wording

      The shareholder or nominee who is registered on the record date in the share register and in a central securities depository register pursuant to Chapter 4 of the Swedish Central Securities Depositories and Financial Instruments Accounts Act (1998:1479) or any person who is registered in a central securities depository account pursuant to Chapter 4, Section 18 first paragraph 6-8 of the mentioned Act, shall be deemed to be authorised to exercise the rights set out in Chapter 4, Section 39 of the Companies Act (2005:551).

      The company’s CEO shall be authorized to make such minor formal adjustments of the resolution as might be necessary in connection with registration with the Swedish Companies Registration Office.


      Item 14: Resolution on authorization for the board of directors regarding new issues

      The board of directors proposes that the annual shareholders’ meeting resolves to authorize the board of directors to, at one or several occasions, during the time up until the next annual shareholders’ meeting, with or without deviation from the shareholders’ preferential rights, resolve to issue shares and/or convertibles.

      A new issue should be able to be made with or without provisions regarding contribution in kind, set-off or other conditions.

      In case the authorization is used for a new issue of shares, the total number of shares that may be issued shall not exceed 4,411,467 shares, corresponding to 20 per cent of the total number of existing shares in the company at the time of the annual shareholders’ meeting and the subscription price shall be on market terms (subject to customary new issue discount, as applicable). The purpose of the authorization as regards new issues of shares is to be able to source working capital, to be able to execute and finance acquisitions of companies as well as to enable new issues to industrial partners within the framework of partnerships and alliances.

      In case the authorization is used for issues of convertibles, such issue must only be made within the financing agreement that the company on 29 December 2017 entered into with Nice & Green S.A. (”N&G”) and the total number of shares that may be issued upon conversion of convertibles issued thereunder shall not exceed 12,000,000 shares. The conversion rate shall be determined in accordance with the provisions in the financing agreement with N&G which stipulate that the conversion rate for convertibles issued to N&G shall amount to the higher of SEK 6 and 92 per cent of the lowest daily volume weighted average price for the company’s share during the 5 trading days preceding the day for the request for conversion. Due to issue technical reasons, each issue resolution regarding convertibles has to stipulate a minimum conversion rate which pursuant to the financing agreement with N&G is stipulated to be SEK 6. At each issue resolution, this minimum conversion rate forms the basis for the maximum numbers of shares that may be issued upon conversion of issued convertibles. Each tranche of convertibles under the financing agreement amounts to SEK 6,000,000 and the stipulated maximum number of shares of 12,000,000 thereby enables the company to draw 12 tranches under the financing agreement with N&G prior to the next annual shareholders’ meeting. It should however be noted that as long as 92 per cent of the lowest daily volume weighted average price for the company’s share during the 5 trading days preceding the day for the request for conversion exceeds SEK 6, the conversion rate so calculated will be applied and the number of shares issued at conversion will then be lower than the maximum number as per the above. For further information regarding the financing agreement with N&G, please refer to the company’s press release issued on 29 December 2017.

      The purpose of the authorization as regards issue of convertibles is to be able to draw tranches under the financing agreement with N&G.

      Upon full utilization of the authorization, a maximum of 16,411,467 shares will be issued or alternatively be issued upon conversion, which corresponds to a total dilution effect of approximately 42.7 per cent. However, please see above for a description regarding the number of shares that can be issued pursuant to the financing agreement with N&G.

      The company’s CEO shall be authorized to make such minor formal adjustments of the resolution as might be necessary in connection with registration with the Swedish Companies Registration Office.


      Item 15: Resolution on (A) employee option program; and (B) directed issue of warrants and approval of transfer of warrants

      The board of directors proposes that the annual shareholders’ meeting resolves to adopt an employee option program for certain employees and key consultants who are active within the Saniona Group in Denmark.

      The purpose of the proposed employee option program (the “Employee Option Program 2018/2023”) is to secure a long-term commitment for the employees and key consultants within the Saniona Group through a compensation system which is linked to the company’s future value growth. Through the implementation of a share-based incentive program, the future value growth in the company is encouraged, which implies common interests and goals for the shareholders of the company and key persons. Such share-based incentive program is also expected to increase Saniona’s possibilities to retain competent persons.

      A. The board of directors’ proposal to resolution on Employee Option Program 2018/2023

      The board of directors proposes that the annual shareholders’ meeting resolves to adopt the Employee Option Program 2018/2023 in accordance with the following substantial guidelines:

      1. The Employee Option Program shall be comprised by a maximum of 34,500 employee options.

      2. Each employee option entitles the holder a right to acquire one new share in the company against cash consideration at a subscription price amounting to 100 per cent of the average closing price of the company’s share on Nasdaq Stockholm during ten trading days prior to the annual shareholders’ meeting on 24 May 2018. The thus calculated subscription price shall be rounded to the nearest whole öre, whereupon 0.5 öre shall be rounded upwards. The subscription price and the number of shares that each employee option entitles right to may be subject to recalculation in the event of a bonus issue, split, rights issue etc., wherein the recalculation terms in the complete terms and conditions of the warrants shall be applied.

      3. The Employee Option Program 2018/2023 shall comprise 20 employees and key consultants within the Saniona Group. The board of directors shall, within the framework of the resolution from the annual shareholders’ meeting, determine the number of employee options that each participant shall be allotted in according with the following principles.

      Senior employees and key consultants (11 individuals): at maximum of 30,500 options may in the aggregate be allotted to this group and no individual may be allotted more than 12,500 options.

      Technical employees (9 individuals):                            at maximum of 4,000 options may in the aggregate be allotted to this group and no individual may be allotted more than 500 options.

      Employees who are also members of the board of directors, managing director or larger shareholders in the company shall not be entitled to participate in the Employee Option Program 2018/2023.

      4.  Allotment shall take place no later than as of 15 July 2018.  

      5.  The allotted employee options will be vested with 1/48 during 48 months after allotment. Vesting requires, with the exemptions stated below, that the participant is still operational within the Saniona Group as of the date when the respective vesting occurs. If the participant ceases to be operational within the Saniona Group after a vesting date has occurred, but before the last date of exercise, the already vested employee options may be exercised on the ordinary dates of exercise, but further vesting will not take place with the exemption of what is stated below.

      For employees in Saniona A/S (the “Subsidiary”) who are subject to the Danish law (Dan. lov om brug af køberet eller tegningsret til anparter m.v. i ansættelsesforhold (lov nr. 309 af 5. maj 2004)) the following will apply regardless of what has been stated above:

      (i) If the Subsidiary terminates the employee’s employment in the Subsidiary, without the employee having violated the employment relationship, the employee has the right to retain and exercise the allotted and unexercised employee options in accordance with the terms and conditions of the Employment Option Program 2018/2023 (including that vesting shall continue in accordance with the terms and conditions), regardless of the termination of the employment.

      (ii) If the employment is terminated by the employee due to the fact that the Subsidiary, in a substantial way, has violated the employment relationship, the employee has the right to retain and exercise the allotted and unexercised employee options in accordance with the terms and conditions of the Employment Option Program 2018/2023 (including that vesting shall continue in accordance with the terms and conditions), regardless of the termination of the employment.

      (iii) If the employment is terminated due to the fact that the employee (i) achieves the retirement age as defined from time to time within the Saniona Group; (ii) qualifies for Danish retirement pension (Dan. Folkepension) or (iii) suffers of invalidity, the employee has the right to retain and exercise the allotted and unexercised employee options in accordance with the terms and conditions of the Employment Option Program 2018/2023 (including that vesting shall continue in accordance with the terms and conditions).

      (iv) If the employment is terminated by the employee and the Subsidiary has not in a substantial way violated the employment relationship, all rights to the allotted unexercised employee options will expire on the date of the termination of the employment relationship, without notice and without any consideration, regardless if the employee options are vested or not.

      (v)  If the Subsidiary terminates or dismisses the employee due to the employee’s violation of the employment relationship, all rights to the allotted unexercised employee options will expire on the date of the termination of the employment relationship, without notice and without any consideration, regardless if the employee options are vested or not.

      6. The employee options shall not constitute securities and shall not be able to be transferred or pledged. However, in the event of death, the rights constituted by the employee options shall accrue to the beneficiaries of the holder of the employee options.

      7. The employee options shall be allotted without consideration. The holders can exercise allotted and vested employee options during 30 days from the day following after the announcement of the company’s quarterly reports, or for full year, the year-end report, the first time after the announcement of the quarterly report for the first quarter of 2022 and the last time after the announcement of the quarterly report for the third quarter of 2023. If the company does not render any quarterly report or year-end report after the end of any calendar quarter, the allotted and vested employee options may instead be exercised during the last month of the following calendar quarter, the first time in June 2022 and the last time in December 2023.

      8. Participation in the Employee Option Program 2018/2023 requires that such participation is in accordance with applicable laws, as well as that such participation can take place with reasonable administrative costs and financial efforts according to the company’s opinion.

      9. The employee options shall be governed by separate agreements with each respective participant. The board of directors shall be responsible for the preparation and management of the Employee Option Program 2018/2023 within the above mentioned substantial terms and guidelines, and by taking into account such minor adjustments that may be required due to tax reasons in Denmark. In extraordinary cases, the board of directors is entitled to limit the extent of the Employee Option 2018/2023, or terminate the Employee Option program in advance, in whole or in part.

      B. The board of directors’ proposal to resolution on a directed issue of warrants and approval of transfer of warrants

      In order to enable the company’s delivery of shares under the Employee Option Program 2018/2023, the board of directors proposes that the annual shareholders’ meeting resolves on a directed issue of a maximum of 34,500 warrants in accordance with the following terms and conditions:

      1.  The warrants shall be issued without consideration and the warrants may only, with deviation from the shareholders’ preferential rights, be subscribed for by the Subsidiary. The reason for the deviation from the shareholders’ preferential rights and the reason for that the warrants are issued without consideration are due to that the warrants are issued as part of the implementation of the Employee Option Program 2018/2023. In the light of the above, the board of directors considers that it is for the benefit of the company and its shareholders that key persons within the Saniona Group are offered to participate in the Employee Option Program 2018/2023.

      2. Subscription shall be made no later than as of 31 July 2018. The board of directors shall be entitled to postpone the last day for subscription.

      3. Each warrant entitles the holder a right to acquire one new share in the company against cash consideration at a subscription price amounting to 100 per cent of the average closing price of the company’s share on Nasdaq Stockholm during ten trading days prior to the annual shareholders’ meeting on 24 May 2018. The thus calculated subscription price shall be rounded to the nearest whole öre, whereupon 0.5 öre shall be rounded upwards. The subscription price and the number of shares that each warrant entitles right to may be subject to recalculation in the event of a bonus issue, split, rights issue etc.

      4. The warrants may be exercised during the time period from and including the registration of the warrants at the Swedish Companies Registration Office (Sw. Bolagsverket) to and including 31 December 2023.

      5. The shares issued upon exercise of a warrant shall confer right to dividends as from the first time on the record date for dividends that occurs immediately following effectuation of subscription.

      6. If all warrants are exercised for subscription of new shares, the share capital will increase with SEK 1,725.

      7. The company’s CEO shall be entitled to make such minor adjustments of the issue resolution that might be necessary in connection with registration with the Swedish Companies Registration Office.

      Further, the board of directors proposes that the annual shareholders’ meeting shall resolve to approve that the Subsidiary may transfer warrants to the participants in the Employee Option Program without consideration in connection with the exercise of employee options in accordance with the terms and conditions under Section A above.

      Other information regarding the Employee Option Program 2018/2023

      The proposal of the Employee Option Program 2018/2023 has been prepared by the board of directors of the company. When preparing the proposal, the board of directors has considered that the Employee Option Program 2018/2023 is intended for individuals who are active in Denmark. The terms and conditions of the Employee Option Program 2018/2023 have therefore been prepared in order to comply with market practice in Denmark.

      The Employee Program 2018/2023 will be accounted for in accordance with “IFRS 2 – Share based payments”. IFRS 2 stipulates that the options shall be expensed as personnel costs over the vesting period and will be accounted for directly against equity. Personnel costs in accordance with IFRS 2 do not affect the company’s cash flow. The board of directors has made the assessment that the Employee Option Program will not trigger any social costs for the company.

      The employee options do not have a market value since they are not transferable. However, the board of directors has calculated a theoretical value of the employee options using the “Black Scholes” formula. Assuming a share price at the time of allocation of the options of SEK 28.85 and that 100 per cent of the options are vested, the total cost for the Employee Option Program 2018/2023 is estimated to approximately SEK 435 thousand before tax during the period 2018-2023 calculated in accordance with the Black-Scholes formula, according to IFRS 2.

      It shall be noted that the calculations are based on preliminary assumptions and are only intended to provide an illustration of the outcome.

      In case all warrants under the Employee Option Program 2018/2023 are exercised for subscription of shares, a total of 34,500 new shares will be issued, which corresponds to a dilution of approximately 0.16 per cent of the company’s share capital and votes after full dilution, calculated on the number of shares that will be added upon full exercise of all warrants which have been issued under the Employee Option Program 2018/2023. The key figure earnings per share before taxes for the full year 2017 had thus been changed in such way that the loss per share after taxes had been changed with SEK 0.004 from – SEK 2.297 to – SEK 2.293.

      Since previously, there are two employee option programs, 2015/2019 and 2017/2022, for employees and key consultants within the Saniona Group and an option program, 2018/2024, for the chairman of the board of directors, outstanding.

      In the employee option program 2015/2019 which was resolved upon by the annual shareholders’ meeting in 2015, there are a total of 64,000 employee options outstanding. Each employee option entitles the holder to subscribe for one new share in the company at a subscription price of SEK 20.72 per share. The employee options can be exercised during 30 days from the announcement of the company’s quarterly reports, or for full year, the year-end report, the first time after the announcement of the quarterly report for the first quarter of 2018 and the last time after the announcement of the quarterly report for the third quarter of 2019. In order to secure the employee option program 2015/2019, a total of 64,000 warrants have been issued and in case all of these warrants are exercised for subscription, a total of 64,000 new shares will be issued and the company’s share capital will increase with SEK 3,200, which corresponds to a dilution of approximately 0.29 per cent of the company’s share capital and votes after full dilution, calculated on the number of shares that will be added upon full exercise of the warrants which have been issued under the employee option program 2015/2019.

      In the employee option program 2017/2022 which was resolved upon by the annual shareholders’ meeting in 2017, there are a total of 38,750 employee options outstanding. Each employee option entitles the holder to subscribe for one new share in the company at a subscription price of SEK 41.13 per share. The employee options can be exercised during 30 days from the announcement of the company’s quarterly reports, or for full year, the year-end report, the first time after the announcement of the quarterly report for the first quarter of 2021 and the last time after the announcement of the quarterly report for the third quarter of 2022. In order to secure the employee option program 2017/2022, a total of 38,750 warrants have been issued and in case all of these warrants are exercised for subscription, a total of 38,750 new shares will be issued and the company’s share capital will increase with SEK 1,937.50, which corresponds to a dilution of approximately 0.18 per cent of the company’s share capital and votes after full dilution, calculated on the number of shares that will be added upon full exercise of the warrants which have been issued under the employee option program 2017/2022.

      In the option program 2018/2024 which was resolved upon by the extraordinary shareholders’ meeting on 19 January 2018, there are a total of 217,625 options outstanding. Each option entitles the holder to subscribe for one new share in the company at a subscription price of SEK 33.60 per share. The options can be exercised during 30 days from the announcement of the company’s quarterly reports, or for full year, the year-end report, the first time after the announcement of the quarterly report for the first quarter of 2021 and the last time after the announcement of the quarterly report for the first quarter of 2024. In order to secure the option program 2018/2024 (including social security contributions), a total of 286,003 warrants have been issued and in case all of these warrants are exercised for subscription, a total of 286,003 new shares will be issued and the company’s share capital will increase with SEK 14,300.15, which corresponds to a dilution of approximately 1.28 per cent of the company’s share capital and votes after full dilution, calculated on the number of shares that will be added upon full exercise of the warrants which have been issued under the option program  2018/2024.

      In addition to the Employee Option Program 2018/2023, the Nomination Committee has proposed that the annual shareholders’ meeting on 24 May 2018 also resolves to adopt an option program for certain members of the board of directors in the company. In connection with the option program, a total of 10,513 warrants will be issued. In case all warrants under the option program are exercised for subscription of shares, a total of 10,513 new shares will be issued and the company’s share capital will increase with SEK 525.65, which corresponds to a dilution of approximately 0.05 per cent of the company’s share capital and votes after full dilution, calculated on the number of shares that will be added upon full exercise of all warrants which have been issued under the option program.

      In case all outstanding warrants as well as the warrants proposed to be issued upon resolution by the annual shareholders’ meeting on 24 May 2018 are exercised for subscription of shares, a total of 433,766 new shares will be issued, which corresponds to a dilution of approximately 1.93 per cent of the company’s share capital and votes after full dilution, calculated on the number of shares that will be added upon full exercise of all outstanding and proposed warrants.

      The above calculations regarding dilution and impact on key ratios are subject to re-calculation of the warrants in accordance with the customary recalculation terms included in the applicable warrant terms.


      Item 16: Resolution on (A) option program for certain members of the board of directors; and (B) directed issue of warrants and approval of transfer of warrants

      The Nomination Committee proposes that the annual shareholders’ meeting on 24 May 2018 resolves to adopt an option program for certain members of the board of directors in the company.

      The Nomination Committee considers that a share-based incentive program is a central part of an attractive and competitive remuneration package in order to attract, retain and motivate experienced members of the board of directors and to incentivize the members of the board of directors to perform their outmost on delivering maximal value growth for all shareholders. The Nomination Committee hence considers that the proposed incentive program (the “Option Program”) will increase and strengthen the board of directors’ dedication to the company’s business, improve the loyalty towards the company and be beneficial for the company as well as its shareholders. The details of the Option Program are set out under Section A below.

      In order to secure the company’s undertakings under the Option Program, the Nomination Committee also proposes that the annual shareholders’ meeting resolves on a directed issue of warrants and an approval of transfer of warrants in accordance with Section B below.

      A. The Nomination Committee’s proposal to resolution on implementation of an option program for certain members of the board of directors

      The Nomination Committee proposes that the annual shareholders’ meeting resolves to adopt the Option Program in accordance with the following guidelines:

      1. The Option Program shall be comprised by a maximum of 8,000 options.

      2. Each option entitle the holders a right to acquire one new share in the company against cash consideration at a subscription price amounting to 100 per cent of the average closing price of the company’s share on Nasdaq Stockholm during ten trading days prior to the annual shareholders’ meeting on 24 May 2018. The thus calculated subscription price shall be rounded to the nearest whole öre, whereupon 0.5 öre shall be rounded upwards. The subscription price and the number of shares that each option entitles right to may be subject to recalculation in the event of a bonus issue, split, rights issue etc., wherein the recalculation terms in the complete terms and conditions of the warrants shall be applied.

      3. The Option Program shall comprise the members of the board of directors in the company who are not co-founders of the company, excluding the chairman of the board of directors, which, based on the Nomination Committee’s proposal regarding board of directors, means that only Anna Ljung and Carl Johan Sundberg should be entitled to participate in the Option Program. Each participant shall be allotted at maximum 4,000 options.

      4. Allotment shall take place no later than 15 July 2018.  

      5. The allotted options will be vested as follows:

      (i)  1/3 will vest on the date when the annual shareholders’ meeting of 2019 is held;

      (ii)  additionally 1/3 will vest on the date when the annual shareholders’ meeting of 2020 is held; and

      (iii) the remaining 1/3 will vest on the date when the annual shareholders’ meeting of 2021 is held.

      If the number of allotted options is not evenly divisible with 1/3, the number of vested options shall be rounded downwards and any excess options shall be considered vested on the last vesting date. Vesting is conditional upon that the participant still holds the position as member of the board of directors in each date when vesting occurs.

      6. The options shall not constitute securities and shall not be possible to transfer or pledge. However, in the event of death, the rights to vested options shall accrue to the beneficiaries of the holder of the options.

      7. The options shall be allotted without consideration. The holders can exercise allotted and vested options during 30 days from the day following after the announcement of the company’s quarterly reports, or for full year, the year-end report, the first time after the announcement of the quarterly report for the first quarter of 2021 and the last time after the announcement of the quarterly report for the first quarter of 2022. If the company does not render any quarterly report or year-end report after the end of any calendar quarter, the allotted and vested options may instead be exercised during the last month of the following calendar quarter, the first time in June 2021 and the last time in June 2022.

      8. In the event of a public take-over offer, asset sale, liquidation, merger or any other such transaction affecting the company, the options will vest in their entirety and be exercisable in connection with the relevant transaction.

      9. The options shall be governed by a separate agreement with the participant. The company’s CEO shall be responsible for the preparation and management of the Option Program in accordance with the above mentioned substantial terms and guidelines.

      B. The Nomination Committee’s proposal to resolution on a directed issue of warrants and approval of transfer of warrants

      In order to enable the company’s delivery of shares under the Option Program and to secure social security charges which may arise in connection with the Option Program, the Nomination Committee proposes that the annual shareholders’ meeting resolves on a directed issue of warrants and approval of transfer of warrants. The Nomination Committee thus proposes that the annual shareholders’ meeting resolves on a directed issue of a maximum of 10,513 warrants in accordance with the following terms and conditions:

      1.  With deviation from the shareholders’ preferential rights, the warrants may only be subscribed for by a wholly owned subsidiary in the group (the “Subsidiary”). The reason for the deviation from the shareholders’ preferential rights is that the warrants are issued as part of the implementation of the Option Program. In the light of what has been stated above, the Nomination Committee considers that it is for the benefit of the company and its shareholders that the existing members of the board of directors are offered to participate in the Option Program.

      2.  Subscription shall be made no later than 31 July 2018. The board of directors shall be entitled to postpone the last day for subscription.

      3.  The warrants shall be issued without consideration. The reason hereof is due to that the warrants shall be issued as part of the implementation of the Option Program.

      4.  Each warrant entitles the holder a right to acquire one new share in the company against cash consideration at a subscription price amounting to 100 per cent of the average closing price of the company’s share on Nasdaq Stockholm during ten trading days prior to the annual shareholders’ meeting on 24 May 2018. The subscription price shall be rounded to the nearest whole öre, whereupon 0.5 öre shall be rounded upwards. The subscription price and the number of shares that each warrant entitles right to may be subject to recalculation in the event of a bonus issue, split, rights issue etc.

      5.  The warrants may be exercised during the time period from and including the registration of the warrants at the Swedish Companies Registration Office (Sw. Bolagsverket) to and including 30 June 2022.

      6.  The shares issued upon exercise of a warrant shall confer right to dividends as from the first time on the record date for dividends that occurs immediately following effectuation of subscription.

      7. If all warrants are exercised for subscription of new shares, the share capital will increase with SEK 525.65.

      8. The company’s CEO shall be entitled to make such minor adjustments of the issue resolution that might be necessary in connection with registration with the Swedish Companies Registration Office.

      Further, the Nomination Committee proposes that the annual shareholders’ meeting resolves to approve that the Subsidiary may transfer warrants to the participants in the Option Program without consideration in connection with the exercise of options in accordance with the terms and conditions under Section A above or otherwise dispose over the warrants to secure the company’s commitments and costs in relation to the Option Program.

      Other information regarding the Option Program

      The Option Program will be accounted for in accordance with “IFRS 2 – Share based payments”. IFRS 2 stipulates that the options shall be expensed as personnel costs over the vesting period and will be accounted for directly against equity. Personnel costs in accordance with IFRS 2 do not affect the company’s cash flow. Social security costs will be expensed in the income statement according to UFR 7 during the vesting period.

      The options do not have a market value since they are not transferable. However, the Nomination Committee has calculated a theoretical value of the options using the “Black Scholes” formula. Assuming a share price at the time of allocation of options of SEK 25.85 and that 100 per cent of the options are vested, the total cost for the Option Program according to IFRS 2 is estimated to approximately SEK 87 thousand before tax during the period 2018-2022 using the Black-Scholes formula. The total cost for the Option Program during the term of the program, including costs according to IFRS 2 and social security costs, is estimated to approximately SEK 115 thousand. The company’s costs for social charges are proposed to be hedged through a directed issue of warrants as per B above.

      It shall be noted that the calculations are based on preliminary assumptions and are only intended to provide an illustration of the outcome.

      Information on existing incentive programs and dilution effects are presented above in the proposal under item 15.

      The proposal for the Option Program has been prepared by the Nomination Committee.

      Particular majority requirements
      For a valid resolution on the proposals pursuant to items 13 and 14, the proposals have to be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the annual shareholders’ meeting. For a valid resolution on the proposals pursuant to items 15 and 16, the proposals have to be supported by shareholders representing at least nine-tenths of the votes cast as well as of all shares represented at the annual shareholders’ meeting.

      Duty of disclosure at the annual shareholders' meeting
      The shareholders’ are reminded of their right to request information at the shareholders’ meeting pursuant to chapter 7 section 32 of the Swedish Companies Act (Sw. Aktiebolagslagen (2005:551)).

      Accounting documents and complete proposals
      Accounting documents, the audit report, the statement by the auditor on the compliance of the applicable guidelines for remuneration to senior executives and complete proposals for resolutions will be available for the shareholders at the company’s office at Baltorpvej 154, DK-2750 Ballerup, Denmark and at the company website (www.saniona.com) as from no later than on 3 May 2018, and will be sent to the shareholders upon their request to the company, provided that such shareholders state their current address. Copies of the documents will also be available at the annual shareholders’ meeting.

      Number of shares and votes in the company
      The total number of shares and votes in the company amounts to 22,057,335. The company does not hold any own shares.

      ____________________

      Malmö in April 2018

      Saniona AB (publ)

      The Board of Directors

      For more information, please contact

      Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com

      This information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEDT on April 24, 2018.

      About Saniona

      Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, BenevolentAI, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq Stockholm Small Cap and has about 5,300 shareholders. The company’s share is traded under the ticker SANION. Read more at www.saniona.com.

      Attachment


    Attachments

    20180424 - PR - Saniona notice AGM 2018 - UK